Citations

Clear

2960 citation(s) found for "Kim, P".

Lost fractures: prevalence and risk factors for missed costosternal and costal cartilage fractures among patients with radiologic chest wall injury
Forrester, Joseph D , Chaar, Mohamad Abou, Barnes, Andrew T, Bauman, Zachary M, Bendjemil, Samy, Betts, Nizama N, Christie, Benjamin, Dasari, Raaga, WB, Devoe, Earley, Michelle J., Faliks, Bradley , Johns, Tracy J, Johnson, Connie, Junker, Michelle S., Kim, B. D., King, Jonathan, Knight, Ariel W. , Schweibinz, Alexis, Stephens, Daniel, Stuever, Mary, Wang, Simeng , Forrester, Joseph D. , Chaar, Mohamad K. Abou , Stephens, Daniel , Abou Chaar, Mohamad , Kim, Brian D. , King, Jonathan M , Knight, Ariel Whitney , Bauman, Zachary Mitchel , DeVoe, William B. , Johns, Tracy J. , Stuever, Mary, Stephens, Daniel

Mayo Clinic

Trauma Surgery & Acute Care Open | January 9, 2026 | Volume: 11 | Issue: 1 | Pages: e002020

10.1136/tsaco-2025-002020 | PMID 41561394 Get It

Background Costosternal cartilages and the costal margin, collectively termed costal cartilage, are hyaline cartilage connecting ribs to the sternum and to adjacent ribs, respectively. Presence of intact costal cartilage is essential for elasticity of the chest wall. Anecdotally, costal cartilage injuries are underdiagnosed on trauma CT scan in patients with rib fractures. Our aim was to determine a baseline frequency of acute costal cartilage injury among patients presenting with rib fractures. Methods We performed a retrospective cohort study of injured adult patients admitted to Level I/II trauma centers with rib fractures from January 2020 to July 2024. CT images obtained at admission were manually reviewed by chest wall surgeons for presence of costal cartilage injury. Concordance with the original radiology report was obtained. Multivariable regression was used to analyze factors associated with costal cartilage injury and missed cartilage fractures. Results 1441 patients were identified; 197 (14%) had a costal cartilage fracture. A plurality of injuries included falls (n=667, 46%). Median ISS (Injury Severity Score) was 13 (IQR: 9 to 21), median Abbreviated Injury Scale thorax score was 3 (IQR: 3 to 3), and median number of fractured ribs was 3 (IQR: 3 to 7). 294 (21%) patients had radiographic flail segments, and 136 (9%) had sternal fractures. 172 (87%) patients had a costal cartilage fracture missed on initial trauma chest CT. On multivariable analysis, ISS (adjusted OR (aOR) 1.02 (95% CI 1.01 to 1.04), radiographic flail segment (aOR 1.6 (95% CI 1.10 to 2.31)) and presence of sternal fracture (aOR 1.85 (95% CI 1.19 to 2.89)) were associated with costal cartilage fractures. Only the total number of rib fractures was associated with a missed costal cartilage fracture on univariate analysis (OR 1.17 (95% CI 1.01 to 1.36)). Conclusions Costal cartilage injuries are common and frequently are not identified during interpretation of the initial trauma CT. A higher index of suspicion is warranted for costal cartilage fractures among patients with greater injury burden, radiographic flail segment, and sternal fractures. Level of evidence Level III.
Investigating the Potential Role of Capsaicin in Facilitating the Spread of Coxsackievirus B3 via Extracellular Vesicles
Kordbacheh, Ramina , Tilley, Haylee, Briordy, Devin, Waldron, Richard T. , Cutts, William D., Aleman, Jayden, Cook, Alexis, Dhanji, Raeesa, Wong, Lok-Yin Roy , Pandol, Stephen J. , Fairweather, DeLisa, Sin, Jon , Fairweather, DeLisa , Kordbacheh, Ramina , Waldron, Richard T , Aleman, Jayden , Wong, Lok-Yin Roy , Pandol, Stephen J , Sin, Jon , Fairweather, DeLisa , Chatterjee, Shruti , Cutts, William D. , Kim, Brandon J.

Mayo Clinic

International Journal of Molecular Sciences | January 9, 2026 | Volume: 27 | Issue: 2 | Pages: 661

10.3390/ijms27020661 | PMID 41596312 Get It

Coxsackievirus B3 (CVB3) is a picornavirus that causes systemic inflammatory diseases including myocarditis, pericarditis, pancreatitis, and meningoencephalitis. We have previously reported that CVB3 induces mitochondrial fission and mitophagy while inhibiting lysosomal degradation by blocking autophagosome-lysosome fusion. This promotes the release of virus-laden mitophagosomes from host cells as infectious extracellular vesicles (EVs), enabling non-lytic viral egress. Transient receptor potential vanilloid 1 (TRPV1), a heat and capsaicin-sensitive cation channel, regulates mitochondrial dynamics by inducing mitochondrial membrane depolarization and fission. In this study, we found that TRPV1 activation by capsaicin dramatically enhances CVB3 egress from host cells via EVs. Released EVs revealed increased levels of viral capsid protein VP1, mitochondrial protein TOM70, and fission protein phospho-DRP1. Moreover, these EVs were enriched in heat shock protein HSP70, suggesting its role in facilitating infectious EV release from cells. Furthermore, TRPV1 inhibition with capsazepine and SB-366791 significantly reduced viral infection in vitro. Our in vivo studies also found that SB-366791 significantly mitigates pancreatic damage and reduces viral titers in a mouse model of CVB3 pancreatitis. Given the lack of understanding regarding factors that contribute to diverse clinical manifestations of CVB3, our study highlights capsaicin and TRPV1 as potential exacerbating factors that facilitate CVB3 dissemination via mitophagy-derived EVs.
Sex, education and race/ethnicity have distinct effects on amyloid and tau‐PET status
Groot, Colin , Rowe, Christopher C., Giessen, Elsmarieke van de, Flier, Wiesje M. van der, Pijnenburg, Yolande A.L., Visser, Pieter Jelle, Braber, Anouk den, Pontecorvo, Michael J. , Burnham, Samantha C., Lu, Ming , Jagust, William J., Baker, Suzanne L. , Harrison, Theresa, Gispert, Juan Domingo, Shekari, Mahnaz , Minguillón, Carolina, Smith, Ruben, Mattsson‐Carlgren, Niklas, Palmqvist, Sebastian, Strandberg, Olof, Stomrud, Erik, Brickman, Adam, Manly, Jennifer J., Lao, Patrick J., Kreisl, William Charles, Malpetti, Maura, O'Brien, John T, Jäger, Elena, Bischof, Gérard, Drzezga, Alexander, Xie, Fang, Mao, Xiaoxie, Guan, Yihui, Frisoni, Giovanni B, Peretti, Débora Elisa , Skoog, I., Kern, Silke, Sperling, Reisa A., Johnson, Keith A., Risacher, Shannon, Saykin, Andrew J., Carrillo, Maria C., Dickerson, Brad C., Apostolova, Liana G., Rabinovici, Gil D., Barthel, H, Messerschmidt, Konstantin, Vandenberghe, Rik, Laere, Koen J. Van, Spruyt, Laure , Petersen, Ronald, Jack, Clifford R., Franzmeier, Nicolai, Brendel, Matthias, Gnörich, Johannes, Benzinger, Tammie L.S., Lagarde, Julien, Sarazin, Marie , Villeneuve, Sylvia , Poirier, Judes, Seo, Sang Won, Gu, Yuna , Kim, Jun Pyo, Mormino, Beth C., Vossler, Hillary , Rosa‐Neto, Pedro, Therriault, Joseph, Rahmouni, Nesrine, Cash, David M, Schott, Jonathan M, Hanseeuw, Bernard J, Jansen, Willemijn J. , Joie, Renaud La, Rosen, Howard J., Johnson, Sterling C., Christian, Bradley T, Betthauser, Tobey J., Landau, Susan M., O'Bryant, Sid E., Hansson, Oskar H., Ossenkoppele, Rik, Prevent‐AD, ADNI, ADNI‐DOD, A‐Study, MCSA,, O’Brien, John T. , O'Brien, John Tiernan , Groot, Colin , Coomans, Emma M. , Rowe, Christopher C., Doré, Vincent , Feizpour, Azadeh , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Pijnenburg, Yolande A.L. , Visser, Pieter Jelle , Braber, Anouk den , Burnham, Samantha C. , Kennedy, Ian Andrew , Jagust, William J. , Harrison, Theresa M. , Gispert, Juan Domingo , Shekari, Mahnaz , Minguillón, Carolina , Smith, Ruben, Mattsson, Niklas , Palmqvist, Sebastian , Strandberg, Olof, Stomrud, Erik , Brickman, Adam M. , Luchsinger, Jose Alejandro , Manly, Jennifer J. , Lao, Patrick , Malpetti, Maura , Rowe, James B. , Bischof, Gérard N. , Drzezga, Alexander E. , Xie, Fang , Guan, Yihui , Garibotto, Valentina , Frisoni, Giovanni B. , Schöll, Michael , Kern, Silke , Sperling, Reisa Anne , Johnson, Keith A. , Risacher, Shannon L. , Saykin, Andrew J. , Carrillo, María C. , Dickerson, Bradford Clark , Apostolova, Liana G. , Rabinovici, Gil D. , Rullmann, Michael , Messerschmidt, Konstantin, Vandenberghe, Rik , Petersen, Ronald, Jack, Clifford R. , Franzmeier, Nicolai , Brendel, Matthias , Gnörich, Johannes , Benzinger, Tammie L.S. , Lagarde, Julien , Bottlaender, Michel , Poirier, Judes , Seo, Sang Won , Kim, Jun Pyo, Young, Christina B. , Rosa-Neto, Pedro , Therriault, Joseph , Rahmouni, Nesrine , Coath, William , Cash, David M. , Schott, Jonathan M. , Hanseeuw, Bernard , Salman, Yasmine , Malotaux, Vincent , Joie, Renaud La , Rosen, Howard J. , Johnson, Sterling C. , Christian, Bradley T. , Betthauser, Tobey J. , Landau, Susan , O’Bryant, Sid E. , Hansson, Oskar , Ossenkoppele, Rik

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105387 Get It

Abstract Background Sex, education and race/ethnicity are all associated with risk of Alzheimer's disease dementia. Here, we assess the effects of self‐reported sex, educational attainment and race/ethnicity on amyloid‐positivity, and tau‐PET‐positivity in 12,048 (7,394 cognitively unimpaired [CU], 2,177 MCI, and 2,477 dementia) individuals from 42 cohorts worldwide. Method Logistic generalized estimating equations were used to estimate frequency of amyloid‐positivity (using cohort‐specific thresholds for amyloid‐PET [84%] or CSF) and tau‐PET‐positivity (cohort‐specific thresholds of 2SD above mean temporal uptake in amyloid‐negative controls). We assessed: i) sex and APOEε4 ( N = 10,098) associations, to complement earlier findings of a higher frequency of tau‐positivity in females, ii) effects of lower/higher education ( N = 10,970; cohort‐specific median‐split), and iii) effects of race/ethnicity (non‐Hispanic White [hereafter: White], N = 4880; Asian, N = 116; Black or African‐American [hereafter: Black], N = 353; Hispanic, N = 356, only from Northern‐American cohorts). Outcomes were frequency of amyloid‐positivity in CU individuals only, and tau‐PET‐positivity in both amyloid‐positive (AB+) CU and cognitively impaired (CI, i.e. MCI and dementia) individuals. Interaction effects on the relationship between age and amyloid/tau‐positivity were assessed and only retained in the models when significant. Result Female sex was associated with an APOEε4 ‐independent increased frequency of amyloid‐positivity (β=0.51[0.22], p = 0.02) in CU and increase of tau‐positivity in both AB+CU (β=0.27[0.08]) and AB+CI (β=0.37[0.08], both p <0.01). Remarkably, tau‐positivity frequencies of female APOEε4 non‐carriers were equivalent to male APOEε4 carriers in AB+CI (Figure 1). No significant sex* APOE interactions were observed. In CU, higher education was associated with lower amyloid‐positivity frequency (β=‐0.12[0.05], p = 0.02). In contrast, among AB+CU, there was an age*education interaction effect that indicated more pronounced age effects on tau‐positivity in individuals with higher education (age*education:β interaction =0.03[0.01], p <0.01). There were no education effects in AB+CI (Figure 2). In CU, an age*race/ethnicity interaction effect was observed across all non‐White groups compared to White (Hispanic:β interaction =‐0.05[0.01], p <0.01; Black:‐0.04[0.01], p <0.01; Asian:‐0.02[0.01], p = 0.04). This suggests that the impact of age on amyloid‐positivity was less pronounced in non‐White groups. Furthermore, in AB+CI, Hispanic ethnicity was related to higher tau‐positivity frequency than White (β=0.51[0.22], p = 0.02; Figure 3). Conclusion In this multi‐center initiative comprised of clinical and community‐based cohorts, we observed that self‐reported sex, educational attainment and race/ethnicity were related to positivity‐frequencies of Alzheimer's disease pathology.
Imaging Hereditary Cancer Syndromes in the Abdomen and Pelvis
Suman, Garima , Nehra, Avinash , Bohyun, Kim, Nathan, Mark A., Heiken, Jay P. , Kawashima, Akira , Nathan, Mark, Heiken, Jay , Kawashima, Akira

Mayo Clinic

RadioGraphics | January 8, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1148/rg.250106 | PMID 41505282 Get It

Radiologists are uniquely positioned to play a critical role in the detection, surveillance, and characterization of hereditary abdominal cancer syndromes.
Investigating the Use of the Fast Health Care Interoperability Resources (FHIR) Standard to Support Data Activities Across the PCORnet® Infrastructure: Lessons Learned From the FHIR Pilots of the Coordinating Center for PCORnet®
Marsolo, Keith S, Louzao, Darcy, Hart, Kim Ward, Shrader, Peter, Hawley, Jeffrey , Delacqua, Francesco, Thomas, E D, Wick, Joseph, Chamberlain, Alanna M., JONES, WILLIAM S., Rothman, Russell L., Harris, Paul A., Cheng, Alex C., Marsolo, Keith , Hart, Kim, Thomas, Ellis, Wick, Joseph J., Chamberlain, Alanna M. , Rothman, Russell L. , Harris, Paul A. , Cheng, Alex

Mayo Clinic

Medical Care | January 8, 2026 | Volume: 64 | Issue: 3S | Pages: S233-S241

10.1097/mlr.0000000000002236 | PMID 41504752 Get It

Background: Institutions that participate in PCORnet ® transform their local electronic health record (EHR) data into the PCORnet ® Common Data Model (CDM), which is then used to generate data extracts for PCORnet ® Studies. PCORnet ® Studies can also include institutions that do not participate in PCORnet, and for these organizations, the cost of instantiating a PCORnet ® CDM can be prohibitive. Fast Health care Interoperability Resources (FHIR) provides an alternative method of obtaining EHR data. Objective: To determine whether data obtained through FHIR might be a viable study solution for those sites that do not participate in PCORnet. ® This mixed-methods project had 2 objectives: (1) survey sites participating in PCORnet on the availability of FHIR (FHIR survey); (2) compare the coverage of a FHIR-based data extract using REDCap with one from the PCORnet ® CDM across 3 sites (FHIR extract). Methods: (1) FHIR survey: A series of questions were asked about the use of FHIR in a production capacity. (2) FHIR extract: REDCap FHIR and PCORnet ® CDM extracts were created based on study variables from 2 prior PCORnet ® Studies. Data were extracted for 40 patients and concordance measures were computed between the 2 sources. Results: (1) FHIR survey: Of responding organizations, 73% (n=49) reported that FHIR was deployed in a production capacity. (2) FHIR extract: Results were highly variable. Cohen kappa ranged from 0.01 to 0.76 for certain diagnoses, 0.24 to 0.84 for laboratory results, and 0.1 to 0.87 for medications. Conclusions: Despite differences in data, certain studies may be well-suited for FHIR-based extracts.
SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Kim, Aerang, Ballman, K., Wolters, Pamela L. , Heise, Rachel S. , Shern, J., Sundby, R. Taylor , Lindenberg, Liza , Lee, Min-Jung , Rastogi, Shraddha , Shahsavari, Shirin, Tine, Brian A. Van, Meyer, Christian F. , Pratilas, Christine A. , Collins, Natalie B. , Coyne, Geraldine O'Sullivan, Chen, Alice P. , Dombi, Eva, Shrestha, Roshan L., Cichowski, Karen M. , Widemann, B. C., Ballman, Karla V. , Kim, AeRang , Cichowski, Karen , Shern, Jack F. , Sundby, R. Taylor , Kim, AeRang , Ballman, Karla , Shern, Jack F , Sato, Nahoko , Shahsavari, Shirin , Hirbe, Angela C , Van Tine, Brian A , Meyer, Christian , Pratilas, Christine A , Collins, Natalie B , O'Sullivan Coyne, Geraldine , Chen, Alice P , Dombi, Eva , Shrestha, Roshan L , Gross, Andrea M , Reinke, Denise , Widemann, Brigitte C , Heise, Rachel , Wolters, Pamela L. , Hirbe, Angela C. , Tine, Brian A. Van , Dombi, Eva , Gross, Andrea M. , Reinke, Denise K.

Mayo Clinic

Clinical Cancer Research | January 8, 2026 | Volume: 32 | Issue: 6 | Pages: 1068-1077

10.1158/1078-0432.ccr-25-2887 | PMID 41504652 Get It

Abstract Purpose: Combined mTOR and MEK inhibition, critical components of the RAS effector pathway underlying the pathogenesis of neurofibromatosis type 1 (NF1)–related tumors, caused regression in a malignant peripheral nerve sheath tumor (MPNST) transgenic mouse model. The primary objective was to determine the clinical benefit rate in patients with unresectable/metastatic MPNST. Patients and Methods: The study design was a multi-institutional, open-label, Simon two-stage, phase II study of the MEK inhibitor selumetinib and mTOR inhibitor sirolimus. Patients ≥12 years with histologically confirmed MPNST received selumetinib 50 mg twice daily and sirolimus 4 mg once daily, in continuous 28-day cycles. Correlative studies evaluated patient-reported pain, immune signature in peripheral blood, and cell-free DNA (cfDNA). Results: A total of 21 heavily pretreated patients [seven females; median age, 41 years (range, 16–72); and 14 with NF1] with advanced disease enrolled at five participating sites. Clinical benefit was observed in only one of seven in stage 1 and one of 14 patients in stage 2. The median number of cycles was two (range, 1–6). Most common adverse events (AE) were grade ≤2 gastrointestinal toxicity, acneiform rash, hypertriglyceridemia, mucositis, and transaminase elevation. Unlike the preclinical model, early 18F-fluorodeoxyglucose PET scan performed during cycle 1 demonstrated partial metabolic responses in five patients (24%), but these did not correlate with objective responses after cycle 2. cfDNA was able to detect MPNST with the potential to be a biomarker of response. Conclusions: The combination was safe, with manageable and expected AEs, but did not meet study parameters for further evaluation in MPNST. Correlative studies were informative and may guide future therapeutic trials of MPNST.
Targeted deletion of macrophage ferritin heavy chain protects from macrophage ferroptosis in acute respiratory distress syndrome
Zhang, William Z. , Faherty, Lynne , Simmons, Will , Carrasco, Sebastian E. , Hoffman, K., Houghton, Sean , Hsu, Chia-Lang, Haber, Leora, Mancias, Joseph D. , Choi, A.H., Plataki, Maria , Mason, Christopher E. , Cloonan, Suzanne , Zhang, William , Carrasco, Sebastian , Houghton, Sean , Hsu, Chia-Lang , Chung, Kuei-Pin , Ballman, Karla , Redmond, David , Mancias, Joseph D , Schenck, Edward , Mason, Christopher E , Meydan, Cem , Kim, K., Bhatia, Divya , Kallinos, Eleni , Hoffman, Katherine L., Haber, Leora , Meydan, Cem , Mirchandani, Ananda S. , Walmsley, Sarah R. , Goyal, Parag , Ballman, Karla V. , Choi, Augustine M.K.

Mayo Clinic

No container title available | January 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5276478/v1 | PMID 41542049 Get It

Abstract Ferritin, consisting of ferritin heavy chain (FTH1) and light chain (FTL) subunits, is an essential intracellular iron storage protein fundamental for cellular function. However, the source and the biological role of extracellular ferritin (ex-ferritin) are less understood. Recent studies have linked elevated serum ex-ferritin with adverse outcomes in individuals with acute respiratory distress syndrome (ARDS). In this study, we demonstrate that both FTH1 and FTL are significantly enriched in the serum, blood monocytes, and alveolar macrophages (AMs) of individuals with ARDS, a phenomenon we successfully replicate in a murine hyperoxia-induced acute lung injury (HALI) model. We show that FTH1 is consistently upregulated in macrophages during lung injury development, and mice with a targeted deletion of FTH1 in myeloid (LysMcre) or resident lung macrophage (Cd11ccre) populations exhibit attenuated HALI. This reduced injury is linked to macrophage resistance to ferroptotic cell death, ferritinophagy, altered airway inflammatory responses, and lower lung extracellular iron and higher levels of FTL-ex-ferritin. Transplantation of FTL-ex-ferritin-enriched bronchoalveolar lavage fluid to wild-type mice protected against HALI. The ratio of FTL-ex-ferritin to FTH1 in the serum of individuals with ARDS who died was higher than that of those that survived, suggesting that the balance between FTH1 and FTL may play a role in injury modulation. Our findings highlight macrophage ferritin as a key regulator of macrophage survival and the response of the lung to injury, presenting a potentially targetable pathway for ARDS treatment.
Current state of mammography-based artificial intelligence for future breast cancer risk prediction: a systematic review
Lowry, Kathryn P. , Jeong, Han Eol , Kim, Ki Hwan , Hughes, Kevin S. , Lee, Christoph I. , Kerlikowske, Karla, Vachon, CM, Kerlikowske, Karla , Kerlikowske, Karla M , Vachon, Celine M. , Hughes, Kevin , Yala, Adam

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 6, 2026 | Volume: 118 | Issue: 3 | Pages: 392-403

10.1093/jnci/djag002 | PMID 41501990 Get It

Abstract Background There is growing interest in artificial intelligence (AI) models for predicting future breast cancer. We performed a systematic review of studies of mammography-based AI models for future breast cancer risk prediction to summarize current evidence, identify knowledge gaps, and inform future research directions. Methods We searched 6 databases for studies from January 1, 2012, to February 28, 2025, that evaluated mammography-based AI models for future breast cancer risk prediction. We extracted study design, participants’ race and ethnicity, geographic origin, mammogram type, vendor, prediction time frame, breast cancer type predicted, external validation, and exclusion of cancers diagnosed on the index screening mammogram. Areas under the receiver operating curve (AUCs) were summarized overall and by study characteristics. Results A total of 41 studies met our inclusion criteria. All studies were retrospective, and most used 2D mammograms (n = 37 studies) acquired using Hologic equipment (n = 25) and performed in the United States (n = 17); White, non-Hispanic women were most represented. Nearly all (n = 40) studies assessed discrimination performance with a median AUC of 0.71 for no longer than 2-year risk prediction, 0.72 for 3-4 years, and 0.71 for 5 years or more prediction. Median AUC was 0.75 for studies including index cancers vs 0.68 when excluded. Six studies reported model calibration performance ranging from good to overestimation of risk. Conclusion Future studies should evaluate models using digital breast tomosynthesis, examine performance for aggressive or advanced breast cancer, include diverse populations, and evaluate both discrimination and model calibration. Prospective evaluations are needed to determine the clinical utility of mammography-based AI models for personalized risk-based breast cancer screening before implementation.
Living liver donor safety: Intraoperative considerations in living liver donation—Guidelines from the ILTS–iLDLT group consensus conference 2025
Bhangui, Prashant , Hakeem, Abdul Rahman , Maira, Tommaso Di , Rammohan, Ashwin, Sayed, Blayne A. , Soejima, Yuji , Shingina, Alexandra , Cheah, Yee Lee , McCluskey, Stuart, Spiro, Michael , Ganesh, Swaytha , Rajalingam, Rajesh , Gupta, Subash , Findlay, James Y. , Chieh, Alfred Kow Wei, Sakamoto, Seisuko, Xia, Qiang, Kim, Ki-Hun , Polak, W., Soin, A G, Pomposelli, James J. , Vyas, Mary, Wiggins, Chantal, Mas, Valeria, Taner, Timucin, Broering, Dieter, Chen, Chao-Leng, Burra, Patrizia, Ascher, N. L., Lerut, Jan, Rela, Mohamed, Selzner, Nazia, Balci, Deniz, Olthoff, Kim M. , Polak, Wojciech G. , Hakeem, Abdul , Rammohan, Ashwin , Sayed, Blayne A , McCluskey, Stuart , Findlay, James, Sakamoto, Seisuko , Xia, Qiang , Polak, Wojciech G , Sapisochin, Gonzalo , Pomposelli, James , Selzner, Nazia , Balci, Deniz , Bhangui, Prashant , Di Maira, Tommaso , Gupta, Amar C. , Xia, Qiang , Sapisochín, Gonzalo , Soin, Arvinder S., Taner, Timuçin , Bröering, Dieter C. , Terrault, Norah A. , Burra, Patrizia , Hirschfield, Gideon M. , Lerut, Jan , Rela, Mohamed , Heimbach, Julie K. , Selzner, Nazia

Mayo Clinic

Liver Transplantation | January 5, 2026 | Volume: 32 | Issue: 4 | Pages: 592-608

10.1097/lvt.0000000000000800 | PMID 41490582 Get It

The success of living donor liver transplantation (LDLT) has bridged the growing gap between organ demand and availability in patients with liver failure or liver cancer. Safety of the living liver donor (LLD) is paramount, and astute intraoperative management plays a critical role in ensuring optimal outcomes for them. Given that intraoperative surgical and anesthesia practices vary widely across centers, the International Liver Transplantation Society (ILTS) and the International Living Donor Liver Transplantation Group (iLDLT Group) convened a global consensus conference in Toronto in March 2025 to develop guidelines for intraoperative management of the LLD. This manuscript details the recommendations on intraoperative considerations for the safety of LLD developed by Working Group II of the Consensus Scientific Committee, using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus. Working Group II focused on intraoperative monitoring, fluid and ventilation strategies, surgical techniques for vascular and biliary division, surgeon and center-specific experience, and intraoperative crises planning. These guidelines aim to support both established and emerging LDLT teams to ensure high-quality and safe intraoperative care for the LLD.
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma
Alderuccio, Juan Pablo , Baggio, Diva , Han, Sunwoo , Nizamuddin, Imran , Saha, Aditi, Dong, Ning , Wang, Yucai, Cherng, Hua‐Jay J. , Wagner-Johnston, Nina D., Desai, Amrita, Geethakumari, Praveen Ramakrishnan , Moyo, Tamara K. , Sandoval‐Sus, Jose , EPPERLA, NARENDRANATH, Kamdar, Manali, Tavarozzi, Rita , Danilov, A., Tun, H., Munoz, Javier, Narkhede, Mayur , Maraj, Adrian Matthew, Osborne, Wendy , Calvert, Victoria, El‐Sharkawi, Dima , Hilali, Ammar, Collins, Graham P., Elmusharaf, Nagah, Santarsieri, Anna , Karim, Farheen, Monick, Sarah, Trutzer, Iris Margalit, Can, Jones, Ayers, Amy , Feo, Jacopo Calabrese De, Ghosh, Nilanjan, Treitman, Rachel, Okcu, Izel, Hann, William D., Barrett, Aisling , Deshani, Vismay, Cwynarski, K., Wang, Yucai , Saha, Aditi , Ghione, Paola , Khwaja, Jahanzaib , Saha, Aditi , Wang, Yucai , Cherng, Hua-Jay J , Tolu, Seda , Wagner-Johnston, Nina , Ollila, Thomas A , Grover, Natalie S , Koff, Jean L , Ramakrishnan Geethakumari, Praveen , Sandoval-Sus, Jose , Epperla, Narendranath , Wallace, Danielle S , Kamdar, Manali , Tun, Han W , Narkhede, Mayur S , Rhodes, Joanna , Okosun, Jessica , El-Sharkawi, Dima , Collins, Graham P , Linton, Kim M , Santarsieri, Anna , Baidoun, Firas , Monick, Sarah E, Calabrese De Feo, Jacopo , Sharp, John , Ghosh, Nilanjan , Okcu, Izel , Hann, William , Barrett, Aisling , Deshani, Vismay , Kahl, Brad S , Chavez, Julio C , Olszewski, Adam J , Ghione, Paola , Dong, Ning, Wagner‐Johnston, Nina D. , Grover, Natalie S. , Koff, Jean L. , Epperla, Narendranath , Wallace, Danielle , Kamdar, Manali , Tun, Han W. , Muñoz, Javier, Rhodes, Joanna , Prica, Anca A. , Kühnl, Andrea , Maraj, Adrian , Smith, Jeff , Calvert, Victoria, Linton, Kim , Baidoun, Firas , Sharp, John , Kallam, Avyakta , Abeyakoon, Chathuri , Kahl, Brad S. , Olszewski, Adam J. , Cwynarski, Kate

Mayo Clinic

Blood | January 5, 2026 | Volume: 147 | Issue: 16 | Pages: 1814-1827

10.1182/blood.2025031455 | PMID 41490516 Get It

Abstract Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic) relapse. SCNSL is a devastating event without therapeutic consensus. Thus, we aimed to evaluate treatment outcomes in an international cohort. Progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR, estimated using competing-risk models) were reported. Prognostic factors were identified in a 6-month landmark multivariate analysis. Outcomes after thiotepa autologous stem cell transplant (ASCT) and chimeric antigen receptor (CAR) T-cell therapy (CAR-T) delivered at relapse were compared after propensity score matching (PSM). A total of 1139 patients were included in the analysis (de novo: 537; relapsed SCNSL: 602). Two-year PFS estimates were 40.4%, 43.9%, and 16.2% for de novo SCNSL, CNS-isolated relapse, and synchronous relapse, respectively. Patients with CNS-isolated relapse demonstrated low rates of systemic recurrence (24-month CIR, 6%). Thiotepa-ASCT correlated with longer survival in de novo SCNSL (PFS: hazard ratio [HR], 0.57; P = .005; and OS: HR, 0.62; P = .023) and CNS-isolated relapses (PFS: HR, 0.55; P = .002; and OS: HR, 0.39; P&lt; .0001). ASCT (thiotepa or no thiotepa) also associated with improved survival in synchronous relapses (PFS: HR, 0.57; P = .023; and OS: HR, 0.48; P = .019). Higher survival with thiotepa-ASCT than CAR-T was observed after PSM (PFS: HR, 0.45; P = .005 and OS: HR, 0.41; P = .014). These data support thiotepa-ASCT in eligible patients, particularly de novo disease and CNS-isolated relapses. CNS-isolated relapse was infrequently associated with systemic recurrence, supporting treatment regimens adopted from primary CNS lymphoma.